title: Reirradiation of canine nasal carcinomas treated with coarsely fractionated radiation protocols: 37 cases.
abstract: Data from 37 dogs with nasal carcinomas treated with two or more coarsely fractionated courses of radiation therapy (RT) were retrospectively reviewed. The median radiation dose for the first course of RT was 24 Gray (Gy). All dogs clinically responded, and 11 had complete resolution of signs for a median of 114 days. Dogs were retreated at relapse, with a median dose of 20 Gy, and 26 of 37 dogs (70%) had clinical responses. The second course of RT was initiated at a median of 150 days following completion of the first course. Side effects were mild: four dogs had chronic ocular conditions necessitating medication, one of which required enucleation. Median survival time (ST) from the first dose of RT was 453 days and 180 days from the first dose of the second course of RT. The following factors were examined but were not significant for survival: total RT dose, dose of the first course of RT, complete resolution of clinical signs, use of either chemotherapy or nonsteroidal anti-inflammatory drugs (NSAIDs), and stage (T1/T2 versus T3/T4). Dogs responded well to reirradiation with a subset experiencing chronic ocular side effects.
authors.affiliation: Department of Veterinary Clinical Sciences, Louisiana State University School of Veterinary Medicine, Baton Rouge, LA, USA. tracy.gieger@gmail.com
authors.forename: Tracy
authors.initials: T
authors.lastname: Gieger
authors.forename: Sheri
authors.initials: S
authors.lastname: Siegel
authors.forename: Kari
authors.initials: K
authors.lastname: Rosen
authors.forename: Dorothy
authors.initials: D
authors.lastname: Jackson
authors.forename: Kevin
authors.initials: K
authors.lastname: Ware
authors.forename: Michael
authors.initials: M
authors.lastname: Kiselow
authors.forename: Keijiro
authors.initials: K
authors.lastname: Shiomitsu
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000532:radiotherapy / Q000662:veterinary*; D004283:Dog Diseases / Q000532:radiotherapy; D004285:Dogs; D005260:Female; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy; D009669:Nose Neoplasms / Q000532:radiotherapy / Q000662:veterinary*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome